Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	09/851071	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:30
L2	40	Schmidt Ann Marie	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/31 09:32
L3	274	Stern, David	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/31 09:30
L4	245	Receptor SAME advanced ADJ glycation	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:47
L5	20585	RAGE	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:32
L6	143	(Receptor SAME advanced ADJ glycation) AND (cancer or tumor or mata$10 or neoplas$5)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/10/31 09:44
L7	74	l6 AND (amphoterin caderin integrin hyaluronic)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:43
L10	0	(Receptor SAME advanced ADJ glycation) AND (cancer or tumor or mata$10 or neoplas$5) AND (amphoterin caderin integrin hyaluronic)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/10/31 09:45
L11	186	Ruoslahti NEAR Erkki	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:47
L18	7	tumor ADJ invasion ADJ assay	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:49
L19	727	cell ADJ migration ADJ assay	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:51
L21	1	l19 and l4	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:50

L22	19	((Ruoslahti NEAR Erkki.in.) and integrin) and invasion	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:52
L25	28	l2 and l5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:53
L26	31	l3 and l5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:53
L29	33	l25 OR l26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:54

=> d his

(FILE 'HOME' ENTERED AT 10:06:11 ON 31 OCT 2005)

FILE 'MEDLINE, CANCERLIT, AGRICOLA, CAPLUS, SCISEARCH' ENTERED AT
10:06:24 ON 31 OCT 2005

```
L1          5091 S RAGE OR (RECEPTOR (5W) ADVANC? (5W) GLYCATION?)
L2        138009 S EXTRACELLU? MAT?
L3            65 S L1 (L) L2
L4             8 S L3 AND PY<=1998
L5             4 DUP REM L4 (4 DUPLICATES REMOVED)
L6             4 SORT L5 PY
L7           188 S L1 (L) (AMPHOTERIN OR CADERIN OR INTERGRIN OR HYALURONIC)
L8            82 DUP REM L7 (106 DUPLICATES REMOVED)
L9           588 S L1 AND (TUMOR OR NOEPLAS? OR CANCER?)
L11           39 S L8 AND (TUMOR OR NOEPLAS? OR CANCER?)
L12            2 S L11 AND PY<=1998
L13          118 S L9 AND PY<=1998
L14           21 S L13 AND (INHIBIT? OR SPREAD? OR INVASI? OR MIGRAT?)
L15           12 DUP REM L14 (9 DUPLICATES REMOVED)
L16           12 FOCUS L15 1-
                 E SCHMIDT ANN?/AU
L17          188 S E1
                 E STERN DAVID?/AU
L18           19 S E2
L19          207 S L17 OR L18
L20          149 S L19 AND L1
L21            8 S L19 AND L3
L22            8 S L19 AND L8
L23           15 S L21 OR L22
L24           13 DUP REM L23 (2 DUPLICATES REMOVED)
```

L24 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:691229 CAPLUS
DN 131:317761
TI Inhibition of tumor invasion or spreading based on a soluble receptor for advanced glycation endproducts
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
IN **Schmidt, Ann Marie**; Stern, David
AB The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble **receptor** for **advanced glycation** endproducts (**RAGE**). Interruption of cellular **RAGE-extracellular matrix** (**amphoterin** and/or similar structures) interaction appears to be at least one mechanism by which sRAGE limits tumor growth. The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9954485	A1	19991028	WO 1999-US8427	19990416
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6465422	B1	20021015	US 1998-62365	19980417
	CA 2325573	AA	19991028	CA 1999-2325573	19990416
	AU 9934957	A1	19991108	AU 1999-34957	19990416
	EP 1071794	A1	20010131	EP 1999-916699	19990416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002512038	T2	20020423	JP 2000-544814	19990416
	US 2002177550	A1	20021128	US 2001-851071	20010508

- The Clipboard will hold a maximum of 500 items.
- Clipboard items will be lost after eight hours of inactivity.

Display Summary Show 20 Sort by Send to

All: 7 Review: 1

Items 1 - 7 of 7 One page.

1: Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Related Articles, Links

Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
Nature. 2000 May 18;405(6784):354-60.
PMID: 10830965 [PubMed - indexed for MEDLINE]

2: Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al. Related Articles, Links

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.
J Biol Chem. 1995 Oct 27;270(43):25752-61.
PMID: 7592757 [PubMed - indexed for MEDLINE]

3: Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Related Articles, Links

Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.
Cancer Res. 2002 Aug 15;62(16):4805-11.
PMID: 12183440 [PubMed - indexed for MEDLINE]

4: Chou DK, Zhang J, Smith FI, McCaffery P, Jungalwala FB. Related Articles, Links

Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration.
J Neurochem. 2004 Sep;90(6):1389-401.
PMID: 15341523 [PubMed - indexed for MEDLINE]

5: Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Related Articles, Links

Regulation of cell migration by amphoterin.
J Cell Sci. 2000 Feb;113 (Pt 4):611-20.
PMID: 10652254 [PubMed - indexed for MEDLINE]

6: Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM. Related Articles, Links

Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
Ann N Y Acad Sci. 2005 Jun;1043:553-61. Review.